Brian Stephenson Acquires 7,803 Shares of Sensei Biotherapeutics (NASDAQ:FTH) Stock

Sensei Biotherapeutics, Inc. (NASDAQ:FTH) CFO Brian Stephenson purchased 7,803 shares of the firm’s stock in a transaction that occurred on Tuesday, June 30th. The stock was bought at an average price of $24.25 per share, with a total value of $189,222.75. Following the transaction, the chief financial officer directly owned 41,688 shares in the company, valued at $1,010,934. This trade represents a 23.03% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Sensei Biotherapeutics Stock Performance

NASDAQ FTH opened at $22.92 on Friday. The stock has a market cap of $30.76 million, a price-to-earnings ratio of -0.16 and a beta of -0.26. Sensei Biotherapeutics, Inc. has a 1 year low of $6.32 and a 1 year high of $36.76.

Sensei Biotherapeutics (NASDAQ:FTH) last announced its earnings results on Friday, May 15th. The company reported ($131.45) EPS for the quarter. On average, sell-side analysts expect that Sensei Biotherapeutics, Inc. will post -16.61 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages recently commented on FTH. Weiss Ratings assumed coverage on shares of Sensei Biotherapeutics in a research report on Wednesday, June 17th. They set a “sell (d-)” rating on the stock. HC Wainwright initiated coverage on shares of Sensei Biotherapeutics in a report on Monday, June 22nd. They set a “buy” rating and a $60.00 price target on the stock. Robert W. Baird initiated coverage on shares of Sensei Biotherapeutics in a research note on Friday, June 26th. They issued an “outperform” rating and a $57.00 price target on the stock. Finally, BTIG Research upgraded Sensei Biotherapeutics to a “strong-buy” rating in a report on Thursday, June 11th. Two investment analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Sensei Biotherapeutics has a consensus rating of “Buy” and a consensus target price of $58.50.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company applies its proprietary ImmunoPhage platform to create conditionally active biologics designed to stimulate the immune system in the tumor microenvironment while limiting activity in healthy tissue.

Its product pipeline has included experimental therapies such as solnerstotug (formerly SNS-101), a checkpoint inhibitor targeting VISTA, and additional oncology candidates in earlier stages of development.